drugset / Trial / NCT02955056

Ankle Fractures Treated With Teriparatide

NCT02955056

Phase 4 Unknown 10 enrolled Nottingham University Hospitals NHS Trust
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single site feasibility trial to test whether daily administration of Teriparatide, in participants with Weber type B ankle fractures that are being conservatively managed, is superior to the standard care treatment with regard to the rate of healing.

Timeline

Start
2016-10
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug

Indications

No indication recorded.